vs
Side-by-side financial comparison of STRATA Skin Sciences, Inc. (SSKN) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
TRANSACT TECHNOLOGIES INC is the larger business by last-quarter revenue ($11.5M vs $9.3M, roughly 1.2× STRATA Skin Sciences, Inc.). On growth, TRANSACT TECHNOLOGIES INC posted the faster year-over-year revenue change (11.9% vs -3.0%). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-551.0K). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs 3.5%).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
SSKN vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.3M | $11.5M |
| Net Profit | $58.0K | — |
| Gross Margin | 61.8% | 47.6% |
| Operating Margin | 5.3% | -10.1% |
| Net Margin | 0.6% | — |
| Revenue YoY | -3.0% | 11.9% |
| Net Profit YoY | 101.3% | — |
| EPS (diluted) | $0.14 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.3M | $11.5M | ||
| Q3 25 | $6.9M | $13.2M | ||
| Q2 25 | $7.7M | $13.8M | ||
| Q1 25 | $6.8M | $13.1M | ||
| Q4 24 | $9.6M | $10.2M | ||
| Q3 24 | $8.8M | $10.9M | ||
| Q2 24 | $8.4M | $11.6M | ||
| Q1 24 | $6.8M | $10.7M |
| Q4 25 | $58.0K | — | ||
| Q3 25 | $-1.6M | $15.0K | ||
| Q2 25 | $-2.6M | $-143.0K | ||
| Q1 25 | $-2.1M | $19.0K | ||
| Q4 24 | $-4.6M | — | ||
| Q3 24 | $-2.1M | $-551.0K | ||
| Q2 24 | $-91.0K | $-319.0K | ||
| Q1 24 | $-3.4M | $-1.0M |
| Q4 25 | 61.8% | 47.6% | ||
| Q3 25 | 60.4% | 49.8% | ||
| Q2 25 | 56.2% | 48.2% | ||
| Q1 25 | 53.5% | 48.7% | ||
| Q4 24 | 61.4% | 44.2% | ||
| Q3 24 | 60.1% | 48.1% | ||
| Q2 24 | 59.0% | 52.7% | ||
| Q1 24 | 45.6% | 52.6% |
| Q4 25 | 5.3% | -10.1% | ||
| Q3 25 | -16.9% | 0.1% | ||
| Q2 25 | -30.1% | -1.9% | ||
| Q1 25 | -25.0% | -0.1% | ||
| Q4 24 | -44.7% | -10.3% | ||
| Q3 24 | -18.2% | -7.7% | ||
| Q2 24 | -5.7% | -3.8% | ||
| Q1 24 | -42.7% | -12.2% |
| Q4 25 | 0.6% | — | ||
| Q3 25 | -23.4% | 0.1% | ||
| Q2 25 | -33.6% | -1.0% | ||
| Q1 25 | -31.2% | 0.1% | ||
| Q4 24 | -47.6% | — | ||
| Q3 24 | -23.6% | -5.1% | ||
| Q2 24 | -1.1% | -2.8% | ||
| Q1 24 | -49.8% | -9.7% |
| Q4 25 | $0.14 | $-0.11 | ||
| Q3 25 | $-0.36 | $0.00 | ||
| Q2 25 | $-0.62 | $-0.01 | ||
| Q1 25 | $-0.51 | $0.00 | ||
| Q4 24 | $-2.01 | $-0.80 | ||
| Q3 24 | $-0.51 | $-0.06 | ||
| Q2 24 | $-0.03 | $-0.03 | ||
| Q1 24 | $-0.10 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.9M | $20.4M |
| Total DebtLower is stronger | $15.3M | — |
| Stockholders' EquityBook value | $2.9M | $31.1M |
| Total Assets | $30.5M | $44.8M |
| Debt / EquityLower = less leverage | 5.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.9M | $20.4M | ||
| Q3 25 | $7.1M | $20.0M | ||
| Q2 25 | $6.0M | $17.7M | ||
| Q1 25 | $6.5M | $14.2M | ||
| Q4 24 | $7.3M | $14.4M | ||
| Q3 24 | $7.1M | $11.3M | ||
| Q2 24 | $5.5M | $11.1M | ||
| Q1 24 | $5.2M | $10.6M |
| Q4 25 | $15.3M | — | ||
| Q3 25 | $15.3M | — | ||
| Q2 25 | $15.0M | — | ||
| Q1 25 | $15.0M | — | ||
| Q4 24 | $15.0M | — | ||
| Q3 24 | $15.0M | — | ||
| Q2 24 | $15.0M | — | ||
| Q1 24 | $15.0M | — |
| Q4 25 | $2.9M | $31.1M | ||
| Q3 25 | $1.3M | $31.8M | ||
| Q2 25 | $532.0K | $31.3M | ||
| Q1 25 | $3.0M | $30.9M | ||
| Q4 24 | $5.0M | $30.6M | ||
| Q3 24 | $9.4M | $38.4M | ||
| Q2 24 | $9.5M | $38.5M | ||
| Q1 24 | $9.4M | $38.6M |
| Q4 25 | $30.5M | $44.8M | ||
| Q3 25 | $30.7M | $45.0M | ||
| Q2 25 | $29.5M | $44.5M | ||
| Q1 25 | $33.0M | $44.2M | ||
| Q4 24 | $34.9M | $44.0M | ||
| Q3 24 | $39.4M | $50.5M | ||
| Q2 24 | $38.8M | $50.4M | ||
| Q1 24 | $39.2M | $51.9M |
| Q4 25 | 5.28× | — | ||
| Q3 25 | 11.65× | — | ||
| Q2 25 | 28.20× | — | ||
| Q1 25 | 5.04× | — | ||
| Q4 24 | 3.02× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.58× | — | ||
| Q1 24 | 1.59× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-239.0K | $609.0K |
| Free Cash FlowOCF − Capex | $-551.0K | $589.0K |
| FCF MarginFCF / Revenue | -5.9% | 5.1% |
| Capex IntensityCapex / Revenue | 3.4% | 0.2% |
| Cash ConversionOCF / Net Profit | -4.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-4.4M | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-239.0K | $609.0K | ||
| Q3 25 | $-64.0K | $3.6M | ||
| Q2 25 | $-1.9M | $3.6M | ||
| Q1 25 | $-550.0K | $-161.0K | ||
| Q4 24 | $703.0K | $2.4M | ||
| Q3 24 | $-302.0K | $327.0K | ||
| Q2 24 | $591.0K | $636.0K | ||
| Q1 24 | $-804.0K | $-1.5M |
| Q4 25 | $-551.0K | $589.0K | ||
| Q3 25 | $-1.1M | $3.6M | ||
| Q2 25 | $-2.0M | $3.6M | ||
| Q1 25 | $-749.0K | $-171.0K | ||
| Q4 24 | $199.0K | $2.4M | ||
| Q3 24 | $-364.0K | $259.0K | ||
| Q2 24 | $246.0K | $499.0K | ||
| Q1 24 | $-1.5M | $-1.6M |
| Q4 25 | -5.9% | 5.1% | ||
| Q3 25 | -15.6% | 27.1% | ||
| Q2 25 | -26.1% | 25.9% | ||
| Q1 25 | -11.0% | -1.3% | ||
| Q4 24 | 2.1% | 23.2% | ||
| Q3 24 | -4.1% | 2.4% | ||
| Q2 24 | 2.9% | 4.3% | ||
| Q1 24 | -22.6% | -14.9% |
| Q4 25 | 3.4% | 0.2% | ||
| Q3 25 | 14.7% | 0.5% | ||
| Q2 25 | 0.8% | 0.1% | ||
| Q1 25 | 2.9% | 0.1% | ||
| Q4 24 | 5.3% | 0.1% | ||
| Q3 24 | 0.7% | 0.6% | ||
| Q2 24 | 4.1% | 1.2% | ||
| Q1 24 | 10.7% | 1.0% |
| Q4 25 | -4.12× | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
TACT
Segment breakdown not available.
